Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 Click here to read this article as a CME course

First Published Online January 28, 2009
The Oncologist, Vol. 14, No. 2, 164-173, February 2009; doi:10.1634/theoncologist.2008-0217
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2008-0217v1
14/2/164    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rabin, K. R.
Right arrow Articles by Whitlock, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rabin, K. R.
Right arrow Articles by Whitlock, J. A.

Pediatric Oncology

Malignancy in Children with Trisomy 21

Karen R. Rabina, James A. Whitlockb

aBaylor College of Medicine, Houston, Texas, USA; bVanderbilt University Medical Center, Nashville, Tennessee, USA

Key Words. Down syndrome • Acute lymphoblastic leukemia • Acute megakaryoblastic leukemia • Myeloproliferative disorders • GATA1 transcription factor • Janus kinase 2

Correspondence: Karen R. Rabin, M.D., Texas Children's Cancer Center, 6621 Fannin Street, CC1510.00, Houston, Texas 77030, USA. Telephone: 832-822-1523; Fax: 832-825-1503; e-mail: krrabin{at}txccc.org

Received September 30, 3008; accepted for publication December 31, 2008; first published online in THE ONCOLOGIST Express on January 28, 2009.

Disclosures

Karen R. Rabin: None; James A. Whitlock: Consultant/advisory role: ITA Partners; Honoraria: Sanofi-Aventis; Research funding/contracted research: Bristol-Myers Squibb.

Section editors Susan M. Blaney and Ross Pinkerton have disclosed no financial relationships relevant to the content of this article.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.

Target audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in pediatric oncology.

Patients with Down syndrome (DS) display a unique spectrum of malignancies, with a 10- to 20-fold higher risk of acute leukemias, and a markedly lower incidence of solid tumors. This review discusses the current understanding of the basis for this distinctive pattern of cancer incidence and the clinical and biologic features of the malignant disorders most frequent in DS individuals: transient myeloproliferative disease, acute megakaryoblastic leukemia, and acute lymphoblastic leukemia. We also review distinctive pharmacogenetic issues, highlighting the differential chemosensitivity and toxicity profiles of DS patients compared with the general population, and epidemiologic studies of protective and adverse environmental risk factors for the development of leukemia.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.
Advertisement